24th Jun 2024 12:42
24 June 2024
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.
The proxy votes cast in respect of the resolutions were as follows:
Resolution | For | Against | Votes withheld | ||
Total votes | % | Total votes | % |
| |
1. To receive the Company's annual report and accounts for the year ended 31 December 2023 | 75,934,412 | 93.27 | 5,924,896 | 6.73 | 2 |
2. To approve the Directors' Remuneration Report | 75,900,186 | 93.23 | 5,924,896 | 6.77 | 10 |
3. To re-appoint John Michael Treacy as a Director of the Company |
74,370,196
| 91.35 |
5,924,896
| 8.65 | 2 |
4. To re-appoint Dawn Coverly as a Director of the Company | 75,700,196 | 92.98 | 5,924,896 | 7.02 | 0 |
5. To re-appoint Nigel Ronald Lee as a Director of the Company | 75,734,386 | 93.03 | 5,924,896 | 6.97 | 2 |
6. To re-appoint PKF Littlejohn LLP as auditor of the Company | 75,734,398 | 93.03 | 5,924,896 | 6.97 |
0
|
7. To authorise the Directors to determine the auditor's remuneration | 75,734,396 | 93.03 | 5,924,896 | 6.97 |
2 |
8. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company | 72,596,681 | 89.17 | 5,924,896 | 10.83 | 0 |
9. Authorise the Directors to allot equity securities disapplying pre-emption rights | 73,960,822 | 90.92 | 6,175,857 | 9.08 | 63,555 |
10. That General Meetings may be called on not less than 14 days' notice | 67,739,369 | 92.52 | 6,175,857 | 7.48 | 8,195,045 |
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
Allenby Capital Limited | +44(0) 20 3328 5656 |
John Depasquale/George Payne (Corporate Finance) | |
Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking) |
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis |
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe | |
Florence Chandler |
About Cizzle Biotechnology
Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Related Shares:
Cizzle Biotech